CRYSTALLINE FORMS
The disclosure relates to crystalline forms of 2-[4-(7-ethyl-5H-pyrrolo[2,3-b]pyrazin-6-yl)-phenyl]-propan-2-ol, characterized by physico-chemical data described herein.
1 . A crystalline form of Compound I:
which is crystalline Form A.
2 . The compound according to claim 1 exhibiting at least two significant peaks in the X-ray diffraction pattern chosen from the following list of at about 7.30, 9.09, 11.08, 11.47, 12.34, and 14.67 degrees 2-theta.
3 . The compound according to claim 1 exhibiting at least three significant peaks in the X-ray diffraction pattern chosen from the following list of at about 7.30, 9.09, 11.08, 11.47, 12.34, and 14.67 degrees 2-theta.
4 . The compound according to claim 1 exhibiting significant peaks in the X-ray diffraction at about 7.30, 9.09, 11.08, 11.47, 12.34, and 14.67 degrees 2-theta.
5 . A crystalline form of Compound I
which is crystalline Form B.
6 . The compound according to claim 5 exhibiting at least two significant peaks in the X-ray diffraction pattern chosen from the following list of at about 7.50, 8.45, 12.46, 13.11, 15.03, 16.90, and 17.78 degrees 2-theta.
7 . The compound according to claim 5 exhibiting at least three significant peaks in the X-ray diffraction pattern chosen from the following list of at about 7.50, 8.45, 12.46, 13.11, 15.03, 16.90, and 17.78 degrees 2-theta.
8 . The compound according to claim 5 exhibiting significant peaks in the X-ray diffraction at about 7.50, 8.45, 12.46, 13.11, 15.03, 16.90, and 17.78 degrees 2-theta.
9 . A crystalline form of Compound I
which is Form C.
10 . The compound according to claim 9 exhibiting at least two significant peaks in the X-ray diffraction pattern chosen from the following list of at about 6.58, 7.35, 8.23, 9.01, 11.87, and 13.12 degrees 2-theta.
11 . The compound according to claim 9 exhibiting at least three significant peaks in the X-ray diffraction pattern chosen from the following list of at about 6.58, 7.35, 8.23, 9.01, 11.87, and 13.12 degrees 2-theta.
12 . The compound according to claim 9 exhibiting significant peaks in the X-ray diffraction at about 6.58, 7.35, 8.23, 9.01, 11.87, and 13.12 degrees 2-theta.
13 . A pharmaceutical composition comprising a compound selected from the group consisting of crystalline Form A, Form B and Form C of Compound I:
together with at least one pharmaceutically acceptable carrier or excipient.
14 . A method of treating a condition in a patient selected from joint inflammation, rheumatoid arthritis, a tumor, and mantle cell lymphoma, comprising administering to a patient in need thereof an effective amount of a a compound selected from the group consisting of crystalline Form A, Form B and Form C of Compound I:
15 . The method according to claim 14 , wherein the condition is joint inflammation.
16 . The method according to claim 15 , wherein the compound is administered in combination with methotrexate.
17 . The method according to claim 14 wherein the condition is rheumatoid arthritis.
18 . The method according to claim 17 , wherein the compound is administered in combination with methotrexate.
19 . The method according to claim 14 wherein the condition is a tumor.
20 . The method according to claim 14 wherein the condition is a mantle cell lymphoma.
21 . A method of inhibiting angiogenesis in a patient, comprising administering to a patient in need thereof an effective amount of a compound selected from the group consisting of crystalline Form A, Form B and Form C of Compound I:
22 . A method of making Form A according to claim 1 , comprising crystallizing Compound I from n-propanol
to give a form which has substantially the XRPD pattern of FIG. 1 .
23 . A method of making Form B according to claim 5 , comprising crystallizing Compound I from n-propanol to give a form which has substantially the XRPD pattern of Form B of FIG. 4 .
24 . A method of making Form C according to claim 9 , comprising crystallizing Compound I from methyltetrahydrofuran to give a form which has substantially the XRPD pattern of FIG. 7 .